November 25, 2026

BSE Limited **Code: 532321**
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited **Code: Zyduslife**
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 25, 2026, titled **"Zydus receives EIR for its manufacturing facility in SEZ II, Ahmedabad"**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.25 14:06:10 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus receives EIR for its manufacturing facility in SEZ II, Ahmedabad

Ahmedabad, India, 25 November, 2026

We wish to inform that the company has received the Establishment Inspection Report (EIR) for the cGMP inspection conducted at its manufacturing site in SEZ II, Ahmedabad, from the USFDA and has been classified as Voluntary Action Indicated (VAI). The inspection was conducted from 21st to 28th September 2026.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

***

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878